Response to “Survival Analysis and Extrapolation Modeling of Time-to-Event Clinical Trial Data for Economic Evaluation: An Alternative Approach” by Bagust and Beale
Restricted accessLetterFirst published online April, 2014
Response to “Survival Analysis and Extrapolation Modeling of Time-to-Event Clinical Trial Data for Economic Evaluation: An Alternative Approach” by Bagust and Beale
BagustABealeS. Survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach [published online July 30, 2013]. Med Decis Making. doi:10.1177/0272989X13497998.
2.
LatimerN. Survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data: inconsistencies, limitations and a practical guide [published online January 22, 2013]. Med Decis Making. doi:10.1177/0272989X12470755.
3.
DemerisNSharplesLD. Bayesian evidence synthesis to extrapolate survival estimates in cost-effectiveness studies. Stat Med. 2006;25:1960–75.
4.
CollettD. Modelling Survival Data in Medical Research. 2nd ed.Boca Raton (FL): Chapman & Hall/CRC, 2003.
5.
BradburnMJClarkTGLoveSBAltmanDG. Survival analysis part III: multivariate data analysis—choosing a model and assessing its adequacy and fit. Br J Cancer. 2003;89(4):605–11.
6.
GuyotPAdesAEOuwensMJNMWeltonNJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.
7.
DaviesABriggsASchneiderJ. The ends justify the mean: outcome measures for estimating the value of new cancer therapies. Health Outcomes Res Med. 2012;3:e25–236.
